Bristol-Myers Squibb Company (BMY) 50.09 $BMY
Research and Markets: Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
Business Wire - 13 mins ago
Research and Markets (http://www.researchandmarkets.com/research/c9fbq3/organ) has announced the addition of the "Worldwide Organ Preservation Solutions Market 2013 - 2019" report to their offering.
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Final Glance: Pharmaceuticals companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb's (BMY) CEO John Elicker on Q1 2014 Earnings - Call Transcript
at The Street - Wed Apr 30, 11:26AM CDT
Bristol-Myers Squibb Company (BMY) Q1 2014 Earnings Conference Call - April 29, 2014 9:00 AM ET
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials Review 2014
M2 - Wed Apr 30, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k5m6xs/metastatic) has announced the addition of the "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Co., Ltd. - Boehringer Ingelheim GmbH - Biotest AG - Astellas Pharma Inc. - Altor BioScience Corporation - National Cancer Institute - The University of Chicago - European Organization for Research and Treatment of Cancer - Icahn School of Medicine at Mount Sinai - Memorial Sloan Kettering Cancer Center - Barts and The London NHS Trust - The Wales Cancer Trials Unit - Northern California Cancer Center - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/k5m6xs/metastatic
Early Glance: Pharmaceuticals companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Papillary Renal Cell Carcinoma Clinical Trials Review 2014
M2 - Wed Apr 30, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2qftt/papillary_renal) has announced the addition of the "Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" report to their offering. Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Papillary Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Papillary Renal Cell Carcinoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Astellas Pharma Inc. - National Cancer Institute - Fox Chase Cancer Center - Memorial Sloan Kettering Cancer Center - UNICANCER Group - Austrian Urogynecology Working Group - Ohio State University Comprehensive Cancer Center - Fred Hutchinson Cancer Research Center - Children's Oncology Group For more information visit http://www.researchandmarkets.com/research/m2...lary_renal
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management
PRWeb - Wed Apr 30, 2:25AM CDT
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Chemical Development Summit, held April 23 - 24, 2014 at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. The meeting featured a tour of the BMS high throughput lab, customer case studies, and discussions of best practices in high throughput research and data management.
Bristol, Merck Q1 sales soft
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Bristol-Myers Squibb (BMY) said EPS rose 12% to 46 cents, beating views by 3 cents. But sales fell 1% to $3.8 bil, missing views of $3.9 bil. Bristol raised the low end of its full-year EPS guidance to $1.65-$1.80, but the midpoint is below analysts'...
Dividend Stock Earnings Roundup: Bristol-Myers Squibb, Merck & Co., and Sanofi
George Budwell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Earnings season has descended upon us once again, with some of the top names in health care reporting today. So, let's take a closer look at Bristol-Myers Squibb , Merck & Co. , and Sanofi 's first-quarter earnings. Bristol-Myers beats...
Watch for Bristol-Myers Squibb to Potentially Rebound After Falling 2.07% Yesterday
Comtex SmarTrend(R) - Tue Apr 29, 3:44PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $48.26 to a high of $49.85. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $49.40 on volume of 12.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Kimberly-Clark Ranks Among Top 20 on '100 Best Corporate Citizens' Survey For Sixth Straight Year
PR Newswire - Tue Apr 29, 3:35PM CDT
Kimberly-Clark Corp. (NYSE: KMB) ranks among the "100 Best Corporate Citizens" for the sixth straight year, appearing at No. 13 in the current issue of Corporate Responsibility Magazine. Kimberly-Clark is one of only four firms to rank in the top 20 for six consecutive years, joining Bristol-Myers Squibb Co., Intel Corp. and IBM Corp. among the top companies since 2009.
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Oncology Drugs Spur a 51% Jump in Profits For Bristol-Myers Squibb
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 1:54PM CDT
Global pharmaceutical giant Bristol-Myers Squibb took the "slow but steady wins the race" approach with its first-quarter earnings release before the opening bell this morning. For the quarter, Bristol-Myers' revenue actually fell 1% to $3.81...
Research and Markets: Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
Business Wire - 13 mins ago
Research and Markets (http://www.researchandmarkets.com/research/c9fbq3/organ) has announced the addition of the "Worldwide Organ Preservation Solutions Market 2013 - 2019" report to their offering.
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Final Glance: Pharmaceuticals companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Bristol-Myers Squibb's (BMY) CEO John Elicker on Q1 2014 Earnings - Call Transcript
at The Street - Wed Apr 30, 11:26AM CDT
Bristol-Myers Squibb Company (BMY) Q1 2014 Earnings Conference Call - April 29, 2014 9:00 AM ET
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials Review 2014
M2 - Wed Apr 30, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k5m6xs/metastatic) has announced the addition of the "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Co., Ltd. - Boehringer Ingelheim GmbH - Biotest AG - Astellas Pharma Inc. - Altor BioScience Corporation - National Cancer Institute - The University of Chicago - European Organization for Research and Treatment of Cancer - Icahn School of Medicine at Mount Sinai - Memorial Sloan Kettering Cancer Center - Barts and The London NHS Trust - The Wales Cancer Trials Unit - Northern California Cancer Center - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/k5m6xs/metastatic
Early Glance: Pharmaceuticals companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Papillary Renal Cell Carcinoma Clinical Trials Review 2014
M2 - Wed Apr 30, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2qftt/papillary_renal) has announced the addition of the "Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" report to their offering. Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Papillary Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Papillary Renal Cell Carcinoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Astellas Pharma Inc. - National Cancer Institute - Fox Chase Cancer Center - Memorial Sloan Kettering Cancer Center - UNICANCER Group - Austrian Urogynecology Working Group - Ohio State University Comprehensive Cancer Center - Fred Hutchinson Cancer Research Center - Children's Oncology Group For more information visit http://www.researchandmarkets.com/research/m2...lary_renal
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management
PRWeb - Wed Apr 30, 2:25AM CDT
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Chemical Development Summit, held April 23 - 24, 2014 at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. The meeting featured a tour of the BMS high throughput lab, customer case studies, and discussions of best practices in high throughput research and data management.
Bristol, Merck Q1 sales soft
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Bristol-Myers Squibb (BMY) said EPS rose 12% to 46 cents, beating views by 3 cents. But sales fell 1% to $3.8 bil, missing views of $3.9 bil. Bristol raised the low end of its full-year EPS guidance to $1.65-$1.80, but the midpoint is below analysts'...
Dividend Stock Earnings Roundup: Bristol-Myers Squibb, Merck & Co., and Sanofi
George Budwell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Earnings season has descended upon us once again, with some of the top names in health care reporting today. So, let's take a closer look at Bristol-Myers Squibb , Merck & Co. , and Sanofi 's first-quarter earnings. Bristol-Myers beats...
Watch for Bristol-Myers Squibb to Potentially Rebound After Falling 2.07% Yesterday
Comtex SmarTrend(R) - Tue Apr 29, 3:44PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $48.26 to a high of $49.85. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $49.40 on volume of 12.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Kimberly-Clark Ranks Among Top 20 on '100 Best Corporate Citizens' Survey For Sixth Straight Year
PR Newswire - Tue Apr 29, 3:35PM CDT
Kimberly-Clark Corp. (NYSE: KMB) ranks among the "100 Best Corporate Citizens" for the sixth straight year, appearing at No. 13 in the current issue of Corporate Responsibility Magazine. Kimberly-Clark is one of only four firms to rank in the top 20 for six consecutive years, joining Bristol-Myers Squibb Co., Intel Corp. and IBM Corp. among the top companies since 2009.
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Oncology Drugs Spur a 51% Jump in Profits For Bristol-Myers Squibb
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 1:54PM CDT
Global pharmaceutical giant Bristol-Myers Squibb took the "slow but steady wins the race" approach with its first-quarter earnings release before the opening bell this morning. For the quarter, Bristol-Myers' revenue actually fell 1% to $3.81...
